(2)
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance
ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued United States Patent 10888898 (the 898 patent) entitled Shielded Ultrasound Transducer and Imaging System Employing the Same from the United States Patent and Trademark Office. This is the 13
th U.S. patent issued to ENDRA for its TAEUS
® technology. ENDRA s goal is to develop applications for our proprietary TAEUS
® technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued 898 patent provides more robust intellectual property (IP) protection for our TAEUS
ENDRA Life Sciences Granted 13th U S Patent for its TAEUS(R) Platform Technology newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Francois Michelon
ResearchAndMarkets.com’s offering.
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5%.
Factors such as the technological advancements in the market are propelling the growth of the human organoids market. Additionally, rising cases of transplants, investments from both private and public sectors are having affect in the growth of human organoids market. However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.
The recent COVID-19 global pandemic has also impacted the human organoids market. Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.
Benchmark indices continued trading near the flat line in early afternoon trade. At 12:20 IST, the barometer index, the S&P BSE Sensex, fell 72.07 points or 0.15% at 47,541.01. The Nifty 50 index slipped 14.85 points or 0.11% at 13,917.75.
In the broader market, the S&P BSE Mid-Cap index lost 0.06% while the S&P BSE Small-Cap index gained 0.04%.
The market breadth was positive. On the BSE, 1,405 shares rose and 1,358 shares fell. A total of 139 shares were unchanged.
Derivatives:
The NSE s India VIX, a gauge of market s expectation of volatility over the near term, rose 1.80% to 21.1650. The Nifty December 2020 futures were trading at 13,934.15, at a premium of 12.05 points compared with the spot at 13,922.10.